Pyrazinamide (pyrazinamide tablet) NDC 10135-735

NDC codes

FDA NDC Directory

Product NDC (as listed)10135-735Labeler and product segments. Claims need a package NDC.

Product NDC at billing width10135-0735Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
10135-735-01	10135073501	100 TABLET in 1 BOTTLE (10135-735-01)Marketed from Mar 1, 2022
10135-735-60	10135073560	60 TABLET in 1 BOTTLE (10135-735-60)Marketed from Mar 1, 2022
10135-735-90	10135073590	90 TABLET in 1 BOTTLE (10135-735-90)Marketed from Mar 1, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pyrazinamide
Generic name (nonproprietary): pyrazinamide tablet
Active ingredients: Pyrazinamide — 500 mg/1
Dosage form: Tablet
Route: Oral
Labeler: MARLEX PHARMACEUTICALS, INC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 080157
Marketing start: Mar 1, 2022
Listing expires: Dec 31, 2026
Identifiers: Product ID 10135-735_45222685-8d74-a7e1-e063-6294a90a9945SPL ID 45222685-8d74-a7e1-e063-6294a90a9945SPL set ID db250a85-2e20-87e9-e053-2a95a90a72b6RxCUI 198181UNII 2KNI5N06TI
Pharmacologic class: Antimycobacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N410135073501 followed by a unit qualifier and the quantity

Package 10135-0735-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 4, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of curren…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 080157

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 080157
Product	Strength	Form · route	Labeler	Product NDC
Pyrazinamide	Pyrazinamide 500 mg/1	TabletOral	ANI Pharmaceuticals, Inc.	70954-484
Pyrazinamide	Pyrazinamide 500 mg/1	TabletOral	American Health Packaging	60687-789